Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Ryan & Maniskas, LLP Class Action Lawsuit Against Isis Pharmaceuticals, Inc.

WAYNE, Pa., Jan. 8, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/isis) announces that a class action lawsuit has been filed in the United States District Court for United States District Court for the Southern District of California on behalf of all persons or entities that purchased the stock of Isis Pharmaceuticals, Inc. ("Isis Pharmaceuticals" or the "Company") (NASDAQ: ISIS) from March 29, 2012 through October 15, 2012, inclusive (the "Class Period").

(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO )

For more information regarding this class action suit, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/isis

Isis Pharmaceuticals, based in Carlsbad, California, is the leading company in gene-blocking antisense drug discovery and development. The Company's flagship product, Kynamro (formerly mipomersen), is designed to treat patients with severe forms of high cholesterol. The Complaint alleges that throughout the Class Period, Isis Pharmaceuticals issued false and misleading statements regarding the safety and efficacy of the drug, as well as reportedly positive results from Kynamro's phase three clinical trial, leading investors to believe that Kynamro would receive approval from the U.S. Food and Drug Administration ("FDA").

On October 16, 2012, an FDA advisory committee posted information on the FDA's website noting that in recent patient studies, 3.1 percent of patients, or 23 people treated with Kynamro developed tumors and three of them died, while only 0.9 percent, or two patients getting a placebo developed tumors. The Endocrinologic and Metabolic Drugs Advisory Committee also noted liver and blood vessel cancers were seen in earlier tests of the drug conducted on mice.

As a result of this disclosure, the price per share of Isis Pharmaceuticals common stock declined $2.88, or nearly 22%, to close that day at $10.27, on heavy trading volume.

If you are a member of the class, you may, no later than February 26, 2013, request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as "lead plaintiff."  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

For more information about the case or to participate online, please visit: www.rmclasslaw.com/cases/isis or contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com.  For more information about class action  cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

CONTACT: 
Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
877-316-3218
www.rmclasslaw.com/cases/isis
rmaniskas@rmclasslaw.com

 

SOURCE Ryan & Maniskas, LLP

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
One look at the comments section of an April column on digital marketing in TechCrunch, and it becomes obvious that contributor Samuel Scott, the marketing and communications director for data analytics software firm Logz.io, pushed a few hot buttons with his take on marketing tech. S...
The current version of Angular is Release Candidate 1. This version changed the way how the framework is distributed – it comes as a set of scoped npm packages now. Any imports of the Angular classes will be done from @angular instead of angular2, for example: import {bootstrap} from ...
Cloud computing changed data analytics for good. It enabled companies to drastically decrease resources and architecture previously assigned with business intelligence departments. It also enabled laymen to run advanced business analytics. Cloud was also the architecture of choice for ...
Are you evaluating a software asset for a potential purchase, investment, decision making for the future, possible termination, etc? Here are some questions to consider. Is this a revenue generating asset? How much revenue does it generate? - Establishing the true business value of a...
If the cloud was once (ever) bleeding edge, now the cloud is sheer necessity for anyone doing anything on the Internet. It has changed the way we architect applications, build IT budgets, grow userbases, even write individual lines of code. As the Internet continues to lambdify, cloud ...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE